Trial Profile
Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Nov 2023
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 07 Nov 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
- 07 Nov 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2024.
- 08 Apr 2022 Status changed from recruiting to active, no longer recruiting.